The role of Cediranib in ovarian cancer.

about

The role of Cediranib in ovarian cancer.

Item

http://www.wikidata.org/entity/Q49966031

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The role of Cediranib in ovarian cancer.

@en

The role of Cediranib in ovarian cancer.

@nl

type

Item

label

The role of Cediranib in ovarian cancer.

@en

The role of Cediranib in ovarian cancer.

@nl

prefLabel

The role of Cediranib in ovarian cancer.

@en

The role of Cediranib in ovarian cancer.

@nl

P1476

The role of Cediranib in ovarian cancer.

@en

P2093

Angela George

http://www.w3.org/2001/XMLSchema#string

Cecilia Orbegoso

http://www.w3.org/2001/XMLSchema#string

Susana Banerjee

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

The role of immune checkpoint inhibition in the treatment of ovarian cancer

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

VEGFs, receptors and angiogenesis.

Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.

P304

1637-1648

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1383384

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gloria Marquina

P577

2017-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28933580

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer